Clinical Trials
18 trialsNCT06026332 2026-02-17
ABLE-41
Ferring Pharmaceuticals
Terminated
NCT04412070 2025-11-21
ALU
Hopital Foch
Terminated
NCT01563796 2025-09-26
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
Medical Diagnostic Laboratories, LLC
Terminated
NCT05819827 2025-04-27
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
Mayo Clinic
Terminated
NCT02053662 2025-03-21
Biomarker Identification for Bladder Cancer Patients
Ohio State University Comprehensive Cancer Center
Terminated
NCT02538809 2025-02-13
Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals
Swiss Paraplegic Research, Nottwil
Terminated
NCT03134027 2024-07-18
Immune PDX
Duke University
Terminated
NCT05699135 2024-04-24
TRAVELER
Pfizer
Terminated
NCT05568407 2023-07-13
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
Pfizer
Terminated
NCT05052372 2022-12-22
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
xCures
Terminated
NCT02735512 2022-08-10
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
University of Southern California
Terminated
NCT02164942 2022-04-26
LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer
Wake Forest University Health Sciences
Terminated
NCT02900248 2019-04-02
N1
CureOne
Terminated
NCT00904514 2018-10-05
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
Terminated
NCT02027649 2017-07-21
Detection of K14 in Bladder Cancer With a Non Invasive Technique
Corporacion Parc Tauli
Terminated
NCT01314664 2015-06-12
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
Endo Pharmaceuticals
Terminated
NCT00918008 2015-03-06
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
Terminated
NCT00216814 2008-04-22
Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Terminated